Cabaletta Bio (CABA) News Today

Squarepoint Ops LLC raised its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 643.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 315,379 shares of the company's stock after bu

Perceptive Advisors LLC trimmed its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 65.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 585,045 shares of the company's stock after selling 1,131,615

Lynx1 Capital Management LP reduced its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 76.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 492,103 shares of the company's stock after selling 1,590,870

Deerfield Management Company L.P. Series C decreased its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 63.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 464,252 shares of the company's stock after selling 794,398 shares

E Fund Management Co. Ltd. grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 1,610.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,424 shares of the company's stock aft

HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a report on Tuesday.

Sofinnova Investments Inc. increased its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 184.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,220,400 shares of the company's stock after purchasing an additional 790,65

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 6,280,000 shares, a drop of 28.4% from the July 31st total of 8,770,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 4.8 days.

Panagora Asset Management Inc. purchased a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 299,801 shares of the company's stock, valued at approximately $2,243,00

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among an

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 8,770,000 shares, a growth of 16.8% from the July 15th total of 7,510,000 shares. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is currently 7.1 days.

Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $35.00 to $20.00 and set an "overweight" rating on the stock in a report on Monday.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.01).

HC Wainwright cut their target price on shares of Cabaletta Bio from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday.

Vanguard Group Inc. grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 6.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,276,222 shares of the company's stock after buying an additional 144,291 sh

Westwood Holdings Group Inc. bought a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 82,228 shares of the company's stock, valued a

Westwood Holdings Group Inc. bought a new position in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 82,228 shares of the company's stock, valued at approximately $1,403

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerag

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 7,180,000 shares, a decline of 24.0% from the June 15th total of 9,450,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the days-to-cover ratio is currently 5.4 days.

Jennison Associates LLC raised its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 110.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,422,984 shares of the company's stock after

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given a consensus rating of "Buy" by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 1-year price objective

Wellington Management Group LLP grew its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 119.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 539,876 shares of the company'

Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price objective on shares of Cabaletta Bio in a report on Friday.

Perceptive Advisors LLC grew its position in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 76.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,003,058 shares of the company's stock after buying an additional 870,567 sh

Cabaletta Bio (NASDAQ:CABA) Shares Gap Up to $12.56

Blackstone Inc. bought a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 347,494 shares of the company's stock, valued at approximately $7,888,00

Cabaletta Bio (NASDAQ:CABA) Shares Up 16.9%

Commodore Capital LP cut its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 24.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,900,000 shares of the company's stock a

TD Asset Management Inc purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 93,630 shares of the company's stock, v

Rafferty Asset Management LLC lifted its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 77.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 209,263 shares of the company's stock after buying an